Status:

NOT_YET_RECRUITING

Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs

Lead Sponsor:

Qilu Hospital of Shandong University

Collaborating Sponsors:

China-Japan Friendship Hospital

The Affiliated Hospital of Qingdao University

Conditions:

Pancreatic Neuroendocine Neoplasms (pNETs)

Eligibility:

All Genders

18-85 years

Brief Summary

The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pa...

Eligibility Criteria

Inclusion

  • 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.

Exclusion

  • Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.

Key Trial Info

Start Date :

August 31 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 31 2027

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT07136701

Start Date

August 31 2025

End Date

July 31 2027

Last Update

August 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Qilu Hospital of Shandong University

Jinan, Shandong, China

Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs | DecenTrialz